Cargando…
Estimating the Prevalence of AATD Patients in the UK to Identify Underdiagnosis and Determine the Eligibility for Potential Augmentation Therapy
PURPOSE: Alpha 1 antitrypsin deficiency (AATD) is a genetic risk factor for chronic obstructive pulmonary disease (COPD). Whilst testing for the condition is relatively simple, there is a disconnect in published literature between genetic epidemiology and numbers of patients known to specialists. Th...
Autores principales: | Newnham, Michael, Quinn, Mark, Turner, Alice M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276585/ https://www.ncbi.nlm.nih.gov/pubmed/37332838 http://dx.doi.org/10.2147/COPD.S395663 |
Ejemplares similares
-
AATD
por: Hood, E
Publicado: (2002) -
Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria
por: Dickey, Amy K., et al.
Publicado: (2020) -
Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease
por: Guo, Shuling, et al.
Publicado: (2014) -
Potential underdiagnosis of osteoporosis in repeated vertebral augmentation for new vertebral compression fractures
por: İlhan, Birkan, et al.
Publicado: (2015) -
NAFLD and AATD Are Two Diseases with Unbalanced Lipid Metabolism: Similarities and Differences
por: Perez-Luz, Sara, et al.
Publicado: (2023)